<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04314622</url>
  </required_header>
  <id_info>
    <org_study_id>YN011B</org_study_id>
    <nct_id>NCT04314622</nct_id>
  </id_info>
  <brief_title>A Study of Supaglutide in Chinese Type 2 Diabetes Patients</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-controlled Study of Supaglutide on the Safety, Pharmacokinetics and Pharmacodynamics, and Efficacy in Chinese Patients With Type 2 Diabetes.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai 6th People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study on the safety, efficacy, pharmacokinetics and pharmacodynamics of Supaglutide dosing
      weekly and bi-weekly in patients with type 2 diabetes mellitus.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 14, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 20, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>Baseline, 7 weeks, 17weeks</time_frame>
    <description>Change from Baseline in Hemoglobin A1c (HbA1c)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Baseline , through 12 weeks for part A; Baseline, through 17 weeks for part B</time_frame>
    <description>Number of Adverse Events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Sign</measure>
    <time_frame>Baseline , through 12 weeks for part A; Baseline, through 17 weeks for part B</time_frame>
    <description>Assessments of Vital Sign</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory Tests</measure>
    <time_frame>Baseline , through 12 weeks for part A; Baseline, through 17 weeks for part B</time_frame>
    <description>Assessments of Laboratory Tests</description>
  </primary_outcome>
  <primary_outcome>
    <measure>12-lead ECGs</measure>
    <time_frame>Baseline , through 12 weeks for part A; Baseline, through 17 weeks for part B</time_frame>
    <description>Assessments of 12-lead ECGs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity Tests</measure>
    <time_frame>Baseline , through 12 weeks for part A; Baseline, through 17 weeks for part B</time_frame>
    <description>Assessments of Immunogenicity Tests</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1c &lt;7%</measure>
    <time_frame>Baseline, 7 weeks, 17weeks</time_frame>
    <description>Percentage of Participants Achieving HbA1c Target &lt;7.0%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycosylated Albumin</measure>
    <time_frame>Baseline, 7 weeks, 17weeks</time_frame>
    <description>Changes from Baseline in Glycosylated Albumin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Blood Glucose</measure>
    <time_frame>Baseline, 7 weeks, 17weeks</time_frame>
    <description>Changes from Baseline in Fasting Blood Glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Blood Insulin</measure>
    <time_frame>Baseline, 7 weeks, 17weeks</time_frame>
    <description>Changes from Baseline in Fasting Blood Insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Blood C-peptide</measure>
    <time_frame>Baseline, 7 weeks, 17weeks</time_frame>
    <description>Changes from Baseline in Fasting Blood C-peptide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Lipid</measure>
    <time_frame>Baseline, 7 weeks, 17weeks</time_frame>
    <description>Changes from Baseline in Blood Lipid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Weight</measure>
    <time_frame>Baseline, 7 weeks, 17weeks</time_frame>
    <description>Changes from Baseline in Body Weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Curve</measure>
    <time_frame>Day1, Day8, Day36 and Day43: Predose, 3, 6, 12, 24, 48, 72, 96, 168 and 336 hours post dose (in part A)</time_frame>
    <description>Area Under the Plasma Drug Concentration-Time Curve from Zero to Infinity (AUC0-∞)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): t½ of Supaglutide</measure>
    <time_frame>Day1, Day8, Day36 and Day43: Predose, 3, 6, 12, 24, 48, 72, 96, 168 and 336 hours post dose (in part A)</time_frame>
    <description>Terminal Elimination Half-life in Plasma (t½)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Tmax of Supaglutide</measure>
    <time_frame>Day1, Day8, Day36 and Day43: Predose, 3, 6, 12, 24, 48, 72, 96, 168, and 336 hours post dose (in part A)</time_frame>
    <description>Time to Maximum Plasma Concentration (Tmax)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Supaglutide (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four investigational doses of Supaglutide administered weekly (or bi-weekly) and subcutaneously (SC) in T2DM patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo(Part A)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered weekly (or bi-weekly) and SC in T2DM patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Supaglutide (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two investigational doses of Supaglutide administered weekly (or bi-weekly) and SC in T2DM patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Part B)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered weekly (or bi-weekly) and SC in T2DM patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Supaglutide</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Supaglutide (Part A)</arm_group_label>
    <arm_group_label>Supaglutide (Part B)</arm_group_label>
    <other_name>Diabegone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Placebo (Part B)</arm_group_label>
    <arm_group_label>Placebo(Part A)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Have diagnosed with type 2 diabetes for at least 3 months before enrollment.

          2. Have diet and exercise intervention only (for part A and part B) or been treated with
             stable dose of metformin as monotherapy for at least 3 months (for part B only)

          3. Have HbA1c ≥7.0% and ≤10.0% as assessed by the central laboratory.

          4. Have a body mass index (BMI) of 20-40 kilograms per square meter (kg/m^2).

        Exclusion Criteria:

          1. Type 1 diabetes (T1D).

          2. Evidences of fasting C-peptide levels&lt;0.81 ng/mL.

          3. History of trauma, infection or surgery within a month;

          4. History of blood donation, blood transfusion or losing more than 450 ml blood within 3
             months.

          5. History of the severe cardiovascular conditions, gastrointestinal diseases, blood
             system diseases, pancreatitis, or malignant tumors.

          6. Evidence of abnormal thyroid function within 6 months before screening.

          7. Positive test results in HBsAg, HCVAB, HIVAB or TPAB.

          8. History of serious mental illness.

          9. History of drug or alcohol abuse.

         10. History of a transplanted organ, acquired or congenital immune system diseases.

         11. Allergy to active ingredients or excipients of the test drug.

         12. Evidence of abnormal result of laboratory examination according to the judgment of
             researchers.

         13. Participated in any interventional medical, surgical, or pharmaceutical study within 3
             months prior to entry into the study.

         14. Previously completed or withdrawn from this study after providing informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weiping Jia, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Endocrinology and Metabolism, Shanghai Sixth People's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yuqian Bao, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Endocrinology and Metabolism, Shanghai Sixth People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>QiuRui Wang</last_name>
    <phone>+862158817202</phone>
    <email>qiurui.wang@innogenpharm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gongping Wang</last_name>
    <phone>+862158817202</phone>
    <phone_ext>803</phone_ext>
    <email>gongping.wang@innogenpharm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Affiliated Zhongda Hospital of Southeast University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Ling, Doctor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 11, 2020</study_first_submitted>
  <study_first_submitted_qc>March 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2020</study_first_posted>
  <last_update_submitted>April 17, 2020</last_update_submitted>
  <last_update_submitted_qc>April 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

